In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic analog Pasireotide | Synthetic analog Lanreotide | |
|---|---|---|---|
| Identity | |||
| Kind | Synthetic analog | Synthetic analog | |
| Area | Growth hormone axis | Growth hormone axis | |
| Evidence | |||
| Amount of evidence | 517 | 585 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 154 (154 in people) | 98 (98 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 76 · 4 active7 more mention it but do not test it | 85 · 8 active25 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
The FDA label for Signifor says: “Adults with Cushing's disease for whom pituitary surgery is not an option or has not been curative”
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Pasireotide | Lanreotide |
|---|---|---|
| Adverse eventsWhole body | 8787 | 6868 |
| Growth hormone and IGF-1Endocrine and hormones |
PepBank is a research reference. Talk to a doctor before you use any peptide.
The FDA label for Somatuline Depot says: “Adults with unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors, to improve progression-free survival”
35296
11810918 |
| Tumor growthEndocrine and hormones | 5643211 | 10688216 |
|---|
| PharmacokineticsPharmacology | 4848 | 2929 |
|---|
| Glycemic controlMetabolic and weight | 56506 | 1616 |
|---|
| Gastrointestinal adverse eventsGastrointestinal | 3131 | 2626 |
|---|
| Gastrointestinal protectionGastrointestinal | 11 | 3535 |
|---|
| Receptor activity and mechanismPharmacology | 6714251 | 252419 |
|---|
| Quality of lifeWhole body | 1515 | 1111 |
|---|
| MortalityWhole body | 761 | 1313 |
|---|
| Liver fat and liver functionLiver | 321 | 1212 |
|---|
| Kidney functionKidney and urinary | 422 | 1010 |
|---|
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
| Outcome | Pasireotide | Lanreotide |
|---|---|---|
| Growth hormone and IGF-1Endocrine and hormonesCompared as: value in the arm that got the peptide, in % | 31.3% Biochemical control rate Dose studied: 40 mg/28 days, with optional titration to 60 mg at months 3 and 712 monthsn = 3582014 | 41% Biochemical control · lanreotide SR (12 patients) n = 202002 |
| Liver fat and liver functionLiverCompared as: value in the arm that got the peptide, in % | −3% Annualized percent change in height-adjusted total liver volume · pasireotide LAR group; ±7 Placebo group; ±7: 6% 1 yearn = 412020 | |
| Tumor growthCancerCompared as: value in the arm that got the peptide, in months | 11.8 months Median progression-free survival Dose studied: 60 mg every 28 daysn not reported2015 | |
| Gastrointestinal adverse eventsGastrointestinalCompared as: value in the arm that got the peptide, in % | 9.4% Drug-related nausea Dose studied: 60 mg every 28 daysn not reported2015 | 26% |
31.3%
Biochemical control rate
Dose studied: 40 mg/28 days, with optional titration to 60 mg at months 3 and 712 monthsn = 3582014
41%
Biochemical control · lanreotide SR (12 patients)
n = 202002
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Pasireotide | Lanreotide |
|---|---|---|
| Kidney functionKidney and urinaryCompared as: difference from placebo, in ml/min/1.73 m2 per year | No comparable result 2 randomized-trial results measure it in another way or another unit. | −0.08 mL/min/1.73 m2 per year difference in annual eGFR decline Dose studied: 120 mg every 4 weeks2.5 yearsn = 309 |
−2.9% Liver volume change Placebo: 1.6% Dose studied: 120 mg every 28 days24 weeksn = 542009 |
16.6 months
Median progression-free survival
Double-blind, placebo: 13.6 months
Dose studied: 120 mg every 28 daysn = 772024
Treatment-related diarrhea
Placebo: 9%
Dose studied: 120 mg every 28 days96 weeksn = 2042014
−3%
Annualized percent change in height-adjusted total liver volume · pasireotide LAR group; ±7
Placebo group; ±7: 6%
1 yearn = 412020
−2.9%
Liver volume change
Placebo: 1.6%
Dose studied: 120 mg every 28 days24 weeksn = 542009
11.8 months
Median progression-free survival
Dose studied: 60 mg every 28 daysn not reported2015
16.6 months
Median progression-free survival
Double-blind, placebo: 13.6 months
Dose studied: 120 mg every 28 daysn = 772024
9.4%
Drug-related nausea
Dose studied: 60 mg every 28 daysn not reported2015
26%
Treatment-related diarrhea
Placebo: 9%
Dose studied: 120 mg every 28 days96 weeksn = 2042014
| Quality of lifeWhole bodyCompared as: difference from placebo, in units per year | No comparable result 2 randomized-trial results measure it in another way or another unit. | −0.03 units per year difference in quality-of-life change Dose studied: 120 mg every 4 weeks2.5 yearsn = 3092018 |
|---|
| MortalityCancerCompared as: value in the arm that got the peptide, in months | No comparable result 1 randomized-trial result measure it in another way or another unit. | 9.5 months Median overall survival · lanreotide, 95% CI 4.8-14.3 Dose studied: 120 mg every 28 daysUp to 1 year or progressionn = 712019 |
|---|
| PharmacokineticsPharmacologyCompared as: value in the arm that got the peptide, in ng.min/l | No comparable result 2 randomized-trial results measure it in another way or another unit. | 1844.3 ng.min/L AUC extrapolated to infinity · 100 microg/h lanreotide infusion Dose studied: 100 microg/h infusion for 8 hours versus 800-microg bolusn = 122004 |
|---|
| Heart functionCardiovascularCompared as: value in the arm that got the peptide, in bpm | 8.2 bpm Postprandial pulse rate increase · pasireotide 300 μg t.i.d.; ± 3.5 Placebo; ± 2.8: 17.1 bpm Dose studied: 300 μg t.i.d.2 weeksn not reported2014 | No comparable result 1 randomized-trial result measure it in another way or another unit. |
|---|
| Gastrointestinal protectionGastrointestinalCompared as: difference from placebo, in % | No randomized trial result 1 result from other study designs. | −6.9% LS mean difference in percentage of days with SC octreotide rescue Dose studied: 120 mg every 4 weeks16 weeksn = 642018 |
|---|
| Treatment adherence and retentionWhole bodyCompared as: value in the arm that got the peptide, in % | No randomized trial result 5 results from other study designs. | 59% Treatment completion Placebo: 86% Dose studied: 120 mg every 28 days72 weeksn = 442024 |
|---|
| Blood pressureLiverCompared as: value in the arm that got the peptide, in % | No randomized trial result 3 results from other study designs. | −13.6% change in baseline HVPG · lanreotide SR 30 mg weekly Dose studied: 30 mg once weekly3 weeksn = 242003 |
|---|
No comparable result
2 randomized-trial results measure it in another way or another unit.
−0.08 mL/min/1.73 m2 per year
difference in annual eGFR decline
Dose studied: 120 mg every 4 weeks2.5 yearsn = 3092018
No comparable result
2 randomized-trial results measure it in another way or another unit.
−0.03 units per year
difference in quality-of-life change
Dose studied: 120 mg every 4 weeks2.5 yearsn = 3092018
No comparable result
1 randomized-trial result measure it in another way or another unit.
9.5 months
Median overall survival · lanreotide, 95% CI 4.8-14.3
Dose studied: 120 mg every 28 daysUp to 1 year or progressionn = 712019
No comparable result
2 randomized-trial results measure it in another way or another unit.
1844.3 ng.min/L
AUC extrapolated to infinity · 100 microg/h lanreotide infusion
Dose studied: 100 microg/h infusion for 8 hours versus 800-microg bolusn = 122004
8.2 bpm
Postprandial pulse rate increase · pasireotide 300 μg t.i.d.; ± 3.5
Placebo; ± 2.8: 17.1 bpm
Dose studied: 300 μg t.i.d.2 weeksn not reported2014
No comparable result
1 randomized-trial result measure it in another way or another unit.
No randomized trial result
1 result from other study designs.
−6.9%
LS mean difference in percentage of days with SC octreotide rescue
Dose studied: 120 mg every 4 weeks16 weeksn = 642018
No randomized trial result
5 results from other study designs.
59%
Treatment completion
Placebo: 86%
Dose studied: 120 mg every 28 days72 weeksn = 442024
No randomized trial result
3 results from other study designs.
−13.6%
change in baseline HVPG · lanreotide SR 30 mg weekly
Dose studied: 30 mg once weekly3 weeksn = 242003
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 76 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Memorial Sloan Kettering Cancer Center439 participantsOct 2009 to Sept 2014
Pancreatic Cancer
Novartis Pharmaceuticals358 participants11 Feb 2008 to 11 Mar 2016
Acromegaly
RECORDATI GROUP337 participants10 Jun 2013 to 25 Jul 2023
Cushing's Disease · Acromegaly · Neuroendocrine Tumors · Pituitary Tumors · Ectopic ACTH Secreting (EAS) Tumors · Dumping Syndrome · Prostate Cancer · Melanoma Negative for bRAF · Melanoma Negative for nRAS
7 more mention it but do not test it. They only measure it or name it in their text.
Top 3 of 85 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Ipsen264 participantsJun 2006 to Apr 2013
Endocrine Tumors
Novartis Pharmaceuticals198 participants19 Jul 2010 to 28 Feb 2017
Acromegaly
Ipsen128 participantsOct 2014 to 16 Feb 2017
Acromegaly
25 more mention it but do not test it. They only measure it or name it in their text.